Floatz logo

Acoramidis

Amyloidosis

BayerSmall moleculePhase 4 / ApprovedActive
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Amyloidosis cohort.

Asset / SponsorPhaseRating
Dexasone
Ascentage Pharma Group Inc.
Phase 3BB
Empagliflozin
Columbia University
Phase 4BB
Tafamidis
Pfizer
Phase 4BB
LENALIDOMIDE
Ascentage Pharma Group Inc.
Phase 3BB
Cyclophosphamide
University of Alabama at Birmingham
Phase 2BB

View all 34 →

Same molecule, other indications

Acoramidis is also rated in:

cardiomyopathyActive
BB
Indicative · Phase 3
64 / 100
View asset →
heart disorderActive
BB
Indicative · Phase 3
64 / 100
View asset →
cardiovascular disorderActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →